34 results
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
Private Issuer
Yes
Disclosure Prohibited under Home Country Law
No
Total Number of directors
Part I: Gender Identity
Female
Male
Non-Binary
Did … Not Disclose
Gender
directors
Part II: Demographic Background
Underrepresented Individual in Home Country Jurisdiction
LGBTQ+
Did Not Disclose Demographic
6-K
EX-99
BLRX
Bioline Rx Ltd
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
Home Country Law
No
Total Number of Directors
Part I: Gender Identity
Female
Male
Non-Binary
Did Not Disclose
Gender
Directors
Part II: Demographic
6-K
EX-99
BLRX
Bioline Rx Ltd
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
information on this Phase 1/2a study, see NCT03593226.
PATIENT CHARACTERISTICS
Total enrollment: 38 patients
Gender: 21 Male, 17 Female
Solid Tumor
6-K
EX-99
BLRX
Bioline Rx Ltd
15 Sep 22
Current report (foreign)
8:39am
or re-enacted before that date;
any gender includes a reference to other genders and the singular includes a reference to the plural and vice versa
6-K
EX-99
jtku90g
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-99
7wowm1c84
16 Dec 20
Current report (foreign)
8:00am
6-K
EX-1
p8exahyb
28 May 19
Current report (foreign)
7:04am
6-K
EX-10.3
ckreyhd44nh5
3 Oct 18
BioLineRx Increases Stake in BL-8040, its Lead Oncology
6:03am
20-F/A
EX-4.40
nad5xooz
31 May 16
Annual report (foreign) (amended)
12:00am
20-F/A
50ih0ik cwz3vsz
23 Mar 15
Annual report (foreign) (amended)
12:00am